The American Journal of Managed Care4d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Pharmaceutical Technology1d
Nivolumab biosimilar by Amgen for Metastatic Melanoma: Likelihood of Approval
Nivolumab biosimilar is under clinical development by Amgen and currently in Phase III for Metastatic Melanoma.
Targeted Oncology10d
FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
FDA approves subcutaneous opdivo qvantig for most solid tumor indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
Monthly Prescribing Reference4d
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.
Pharmaceutical Technology7d
Nivolumab by Bristol-Myers Squibb for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer.
Medical Xpress29d
Study finds increased survival with nivolumab plus ipilimumab vs. chemo for metastatic colorectal cancer
In this prespecified interim analysis, nivolumab plus ipilimumab was compared to chemotherapy. Overall, 303 patients who had not previously received systemic treatment were randomly assigned to ...
Targeted Oncology1d
The Targeted Pulse: Discover the FDA’s Holiday Moves For Solid Tumors, Gastric, and GEJ Cancers
The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...
I-Mab stock jumps 15% following pipeline update
I-Mab (IMAB) stock jumped 15% Monday after the biotech company said it plans to focus on developing givastomig for the treatment of gastric cancers. Read more here.
ascopubs.org25d
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial Nivolumab plus relatlimab demonstrated a statistically ...